Polyploid giant cancer cells lead to evolution of drug resistance in high-grade ovarian cancer.

被引：0
|
作者：
Niu, Na [1 ]
Li, Xiaoran [1 ]
Yao, Jun [1 ]
Sood, Anil [1 ]
Liu, Jinsong [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
CANCER RESEARCH | 2020年 / 80卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
A17
引用
收藏
页码：41 / 42
页数：2
相关论文
共 50 条
  • [21] Mechanistic role of nelfinavir as drug-repurposing strategy against high-grade serous ovarian cancer.
    Subeha, Mahbuba R.
    Goyeneche, Alicia A.
    Telleria, Carlos M.
    CANCER RESEARCH, 2021, 81 (13)
  • [22] Phenotypic and genomic characterization of intratumoral heterogeneity in high-grade serous ovarian cancer.
    Cunnea, Paula
    Curry, Ed
    Nixon, Katherine
    Wulandari, Ratri
    Thol, Kerstin
    Kwok, Chun Hei
    Ploski, Jennifer
    McNeish, Iain
    Christie, Elizabeth
    Bowtell, David
    Fotopoulou, Christina
    CLINICAL CANCER RESEARCH, 2020, 26 (13) : 42 - 42
  • [23] PAX8-directed nanotherapeutics for high-grade serous ovarian cancer.
    Chandrasekaran, Akshaya
    Ahmed, Mariam
    Holub, Nicole
    Wang, Wade
    Hammond, Paula T.
    Elias, Kevin M.
    CANCER RESEARCH, 2021, 81 (13)
  • [24] Singling out tumor heterogeneity and chemoresistance in high-grade serous ovarian cancer.
    Erkan, Erdogan Pekcan
    Dai, Jun
    Zhang, Kaiyang
    Kaipio, Katja
    Lamminen, Tarja
    Mansuri, Naziha
    Suominen, Lasse
    Alkodsi, Amjad
    Huhtinen, Kaisa
    Hietanen, Sakari
    Hynninen, Johanna
    Grenman, Seija
    Carpen, Olli
    Hautaniemi, Sampsa
    Vaharautio, Anna
    CLINICAL CANCER RESEARCH, 2020, 26 (13) : 59 - 59
  • [25] Targeting polyploid giant cancer cells potentiates a therapeutic response and overcomes resistance to PARP inhibitors in ovarian cancer
    Zhang, Xudong
    Yao, Jun
    Li, Xiaoran
    Niu, Na
    Liu, Yan
    Hajek, Richard A.
    Peng, Guang
    Westin, Shannon
    Sood, Anil K.
    Liu, Jinsong
    SCIENCE ADVANCES, 2023, 9 (29)
  • [26] Chemical biology approach to phenotypic intratumor heterogeneity as a source of chemotherapy resistance in high-grade serous ovarian cancer.
    Bulanova, Daria R.
    Kaipio, Katja
    Lamminen, Tarja
    Ianevski, Aleksandr
    Aittokallio, Tero
    Carpen, Olli
    Wennerberg, Krister
    CLINICAL CANCER RESEARCH, 2018, 24 (15) : 62 - 63
  • [27] DCLK1 mediates tumor stemness and platinum resistance in high-grade serous epithelial ovarian cancer.
    Moxley, Katherine M.
    Ha, JiHee
    Andrade, Daniel
    Houchen, Courtney
    Dhanasekaran, Danny
    CLINICAL CANCER RESEARCH, 2020, 26 (13) : 66 - 67
  • [28] Elucidating resistance mechanism to PARP inhibitors for the development of novel therapeutic approaches in high-grade serous ovarian cancer.
    Kulbe, Hagen
    Kassuhn, Wanja Nikolai
    Ringel, Frauke
    Welsch, Gabriele
    Treffkorn, Peggy
    Taube, Eliane T.
    Horst, David
    Sehouli, Jalid
    Braicu, Ioana
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [29] Are polyploid giant cancer cells in high grade serous carcinoma of the ovary blastomere-like cancer stem cells
    Salem, Alireza
    Pinto, Karen
    Koch, Meghan
    Liu, Jinsong
    Silva, Elvio G.
    ANNALS OF DIAGNOSTIC PATHOLOGY, 2020, 46
  • [30] WTAP is a prognostic marker of high-grade serous ovarian cancer and regulates the progression of ovarian cancer cells
    Yu, Hai-Lan
    Ma, Xu-Dong
    Tong, Jin-Fei
    Li, Jian-Qiong
    Guan, Xiao-Jing
    Yang, Jian-Hua
    ONCOTARGETS AND THERAPY, 2019, 12 : 6191 - 6201
12345